|
1）Gately K, O’Flaherty J, Cappuzzo F, et al. The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC. J Clin Pathol. 2012; 65: 1-7
|
|
|
|
2）Oxnard GR, Binder A, Janne PA. New targetable oncogenes in non-small-cell lung cancer. J Clin Oncol. 2013; 31: 1097-104
|
|
|
|
|
|
3）Kohno T, Ichikawa H, Totoki Y, et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med. 2012; 18: 375-7
|
|
|
|
|
|
4）Tsuta K, Kohno T, Yoshida A, et al. RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis. Br J Cancer. 2014; 110: 1571-8
|
|
|
|
|
|
5）Saito M, Ishigame T, Tsuta K, et al. A mouse model of KIF5B-RET fusion-dependent lung tumorigenesis. Carcinogenesis. 2014; 35: 2452-6
|
|
|
|
|
|
6）Saito M, Shimada Y, Shiraishi K, et al. Development of lung adenocarcinomas with exclusive dependence on oncogene fusions. Cancer Res. 2015; 75: 2264-71
|
|
|
|
|
|
7）Kohno T, Nakaoku T, Tsuta K, et al. Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer. Transl Lung Cancer Res. 2015; 4: 156-64
|
|
|
|
|
|
8）Falchook GS, Ordonez NG, Bastida CC, et al. Effect of the RET inhibitor vandetanib in a patient with RET fusion-positive metastatic non-small-cell lung cancer. J Clin Oncol. 2014. ［Epub ahead of print］
|
|
|
|
|
|
9）Vaishnavi A, Capelletti M, Le AT, et al. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med. 2013; 19: 1469-72
|
|
|
|
|
|
10）Fernandez-Cuesta L, Plenker D, Osada H, et al. CD74-NRG1 fusions in lung adenocarcinoma. Cancer Discovery. 2014; 4: 415-22
|
|
|
|
|
|
11）Nakaoku T, Tsuta K, Ichikawa H, et al. Druggable oncogene fusions in invasive mucinous lung adenocarcinoma. Clin Cancer Res. 2014; 20: 3087-93
|
|
|
|
|
|
12）Cancer Genome Atlas Research N. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014; 511: 543-50
|
|
|
|
|
|
13）Arcila ME, Drilon A, Sylvester BE, et al. MAP2K1 （MEK1） mutations define a distinct subset of lung adenocarcinoma associated with smoking. Clin Cancer Res. 2015; 21: 1935-43
|
|
|
|
|
|
14）Liao RG, Jung J, Tchaicha J, et al. Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. Cancer Res. 2013; 73: 5195-205
|
|
|
|
|
|
15）Nivolumab approved for lung cancer. Cancer Discovery. 2015; 5: OF1
|
|
|
|
|
|
16）Peifer M, Fernandez-Cuesta L, Sos ML, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet. 2012; 44: 1104-10
|
|
|
|
|
|
17）Iwakawa R, Kohno T, Totoki Y, et al. Expression and clinical significance of genes frequently mutated in small cell lung cancers defined by whole exome/RNA sequencing. Carcinogenesis. 2015; 36: 616-21
|
|
|
|
|
|
18）Umemura S, Mimaki S, Makinoshima H, et al. Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis. J Thorac Oncol. 2014; 9: 1324-31
|
|
|
|
|
|
19）Greaves M, Maley CC. Clonal evolution in cancer. Nature. 2012; 481: 306-13
|
|
|
|
|
|
20）Jamal-Hanjani M, Quezada SA, Larkin J, et al. Translational implications of tumor heterogeneity. Clin Cancer Res. 2015; 21: 1258-66
|
|
|
|
|
|
21）de Bruin EC, McGranahan N, Mitter R, et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science. 2014; 346: 251-6
|
|
|
|
|
|
22）Iwakawa R, Kohno T, Anami Y, et al. Association of p16 homozygous deletions with clinicopathologic characteristics and EGFR/KRAS/p53 mutations in lung adenocarcinoma. Clin Cancer Res. 2008; 14: 3746-53
|
|
|
|
|
|
23）Nakanishi H, Matsumoto S, Iwakawa R, et al. Whole genome comparison of allelic imbalance between noninvasive and invasive small-sized lung adenocarcinomas. Cancer Res. 2009; 69: 1615-23
|
|
|
|
|
|
24）Zhang J, Fujimoto J, Zhang J, et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science. 2014; 346: 256-9
|
|
|
|
|
|
25）Vignot S, Frampton GM, Soria JC, et al. Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancer. J Clin Oncol. 2013; 31: 2167-72
|
|
|
|
|
|
26）Giri S, Patel JK, Mahadevan D. Novel mutations in a patient with ALK-rearranged lung cancer. N Engl J Med. 2014; 371: 1655-6
|
|
|
|
|
|
27）Janne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015; 372: 1689-99
|
|
|
|
|
|
28）Oike T, Ogiwara H, Tominaga Y, et al. A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1. Cancer Res. 2013; 73: 5508-18
|
|
|
|
|
|
29）Hoffman GR, Rahal R, Buxton F, et al. Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers. Proc Natl Acad Sci U S A. 2014; 111: 3128-33
|
|
|
|
|